Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pathophysiology

Altered Extracellular Vesicle Concentration, Cargo, and Function in Diabetes

  1. David W. Freeman1,
  2. Nicole Noren Hooten1,
  3. Erez Eitan2,
  4. Jamal Green1,
  5. Nicolle A. Mode1,
  6. Monica Bodogai3,
  7. Yongqing Zhang4,
  8. Elin Lehrmann4,
  9. Alan B. Zonderman1,
  10. Arya Biragyn3,
  11. Josephine Egan5,
  12. Kevin G. Becker4,
  13. Mark P. Mattson2,
  14. Ngozi Ejiogu1 and
  15. Michele K. Evans1⇑
  1. 1Laboratory of Epidemiology and Population Science, National Institute on Aging, National Institutes of Health, Baltimore, MD
  2. 2Laboratory of Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD
  3. 3Laboratory of Molecular Biology and Immunology, National Institute on Aging, National Institutes of Health, Baltimore, MD
  4. 4Laboratory of Genetics and Genomics, National Institute on Aging, National Institutes of Health, Baltimore, MD
  5. 5Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD
  1. Corresponding author: Michele K. Evans, me42v{at}nih.gov.
  1. D.W.F. and N.N.H. contributed equally to this work.

Diabetes 2018 Nov; 67(11): 2377-2388. https://doi.org/10.2337/db17-1308
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Cohort design. A and B: Cross-sectional cohorts 1 and 2 of euglycemic individuals and individuals with diabetes. C: Longitudinal cohort design of euglycemic individuals and individuals with prediabetes or diabetes.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Higher plasma EV concentration in individuals with diabetes. A: Plasma-derived EVs isolated from six individuals (two from each longitudinal group), two EV-depleted plasma samples, and cell lysate from 3T3-L1 cells were subjected to SDS-PAGE and probed for EV-enriched proteins. B: Electron microscopy of EVs isolated from plasma exhibit expected morphology and size. Scale bar = 500 nm. C and D: EVs were isolated from the cross-sectional diabetes cohort and concentration and size distribution were analyzed using NTA. Size distribution was averaged for each group. The area under the curve in C is shown in D. P < 0.022 by linear mixed-model regression. E: EV concentration for cross-sectional cohort 2. P < 0.016 between white euglycemic individuals (Eu) and individuals with diabetes (DM) by linear mixed-model regression. AA, African American. F: EV concentration in a longitudinal cohort showed a significant difference between the euglycemic→euglycemic and prediabetes→diabetes groups (P = 0.01) (DM, individuals with diabetes; PreDM, individuals with prediabetes). The histogram in D and line in F represent the predicted value from linear mixed-model regression. P value was determined by linear mixed-model regression on log-transformed values. G: NTA analysis of plasma EVs isolated from euglycemic individuals (n = 6) and individuals with diabetes (n = 6) from cross-sectional cohort 1 using differential ultracentrifugation. EVs were isolated from both the 10,000g and 120,000g fractions as indicated (**P < 0.01). H: Antibodies against the cell-specific markers were used to capture intact euglycemic and diabetic (n = 22/group) PKH-labeled EVs from the cross-sectional cohort 2. Fluorescent intensity was measured, and log-transformed values are shown. Dashed white line indicates average IgG signal (n = 3) for each assay. *P < 0.05 by Student t test.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    Insulin signaling proteins are present in EVs and are affected by diabetes status. A: EV protein levels of the leptin receptor and phosphorylated (p)IR were measured using ELISAs, and the lines represent the predicted values from linear mixed-model regression. P = 0.01 for leptin receptor and P = 0.051 for phospho-IR for euglycemia→euglycemia group (n = 19) compared with the euglycemia→diabetes (n = 19) group (DM, diabetes; Eu, euglycemic; PreDM, prediabetes). B: EV protein levels and concentration were quantified in the longitudinal cohort at both times (euglycemia→euglycemia, n = 19, and euglycemia→diabetes, n = 19). A cross-sectional analysis was performed using time 2 (euglycemia = 19 and diabetes = 39). The relationship with HOMA-B and HOMA-IR was analyzed using linear mixed-model regression. Significant changes are indicated, and the direction of change is indicated by the up and down arrows.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4

    Prolonged exposure to insulin impairs insulin signaling in primary cortical neurons and increases EV secretion. Neurons were untreated, pretreated with insulin (Ins.) (200 nmol/L) for 48 h, and then either untreated or treated for 30 min with insulin (200 nmol/L) or treated only for 30 min with insulin as indicated. A: Neurons were lysed and immunoblotted with anti–phosphorylated (p)AKT, total AKT, or actin antibodies. B: The conditioned media was collected from treated neurons, and the EVs were isolated by differential ultracentrifugation. EVs were lysed and analyzed by SDS-PAGE along with cell lysate from primary cortical neurons. Samples were probed using antibodies for positive and negative EV markers. C and D: NTA was used to analyze the size distribution and concentration of EVs isolated from conditioned media from treated and untreated neurons (n = 4). E: Neurons treated as described above were also incubated with 200 nmol/L wortmannin. Cell lysates were collected and immunoblotted with an anti-LC3 antibody. Arrow indicates LC3 II, and numbers indicate the ratio of LCII to LCI. Actin was used as a protein loading control. F: EVs were isolated from the conditioned media, and the concentration was measured using NTA (n = 3). All histograms represent the mean (SEM). **P < 0.01, *P < 0.05 by Student t test.

  • Figure 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5

    EVs from individuals with diabetes are preferentially internalized by circulating leukocytes. A: Plasma EVs (6 × 108) from individuals with diabetes (n = 39) and euglycemic individuals (n = 19) from the longitudinal cohort at time 2 were incubated with PBMCs (∼200,000 cells/well) for 24 h. Cells positive for EV internalization (PKH+) were sorted into B cells (CD19+PKH+). B: Classical monocytes (CD14++CD16−PKH+). C: Nonclassical monocytes (CD14−CD16+PKH+). D: Intermediate monocytes (CD14++CD16+PKH+). The histograms represent means (SEM). Statistical significance was assessed by linear mixed-model regression on the log-transformed values to account for skewness of the data. DM, diabetes; Eu, euglycemic. ***P < 0.001.

  • Figure 6
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6

    EVs from individuals with diabetes alter gene expression in monocytes. A: Plasma EVs were pooled (4.5 × 1011) from several individuals from the longitudinal cohort at time 2 and grouped as either diabetic (DM) (n = 2) or euglycemic (EU) (n = 3). Cells not treated with EVs were used as another control (UNT). EVs were incubated with PBMCs for 24 h, and monocytes were isolated. Gene expression was assessed by microarray, and Gene Ontology analysis was performed. Heat map shows significant pathways (P < 0.01) related to apoptosis, immune response, oxidative stress, and vesicle formation. B: Top 20 significant downregulated and upregulated genes from the pathways in A are shown. A P value cutoff of <0.05 was used for significance. Labeling represents control group vs. treatment group. C and D: After incubation with euglycemic or diabetic EVs from cross-sectional cohort 2 (n = 3/group), total RNA and media were collected from the monocytes. Gene-specific primers were used for RT-qPCR analysis of genes from the microarray (C). D: EVs were isolated from the media using ultracentrifugation, lysed, and run along with EV-depleted media on a cytokine panel. Histograms represent the mean (SEM). *P ≤ 0.05, **P < 0.01, ***P < 0.001 by Student t test.

Tables

  • Figures
  • Table 1

    Clinical characteristics of cross-sectional cohorts

    Cross-sectional cohort 1Cross-sectional cohort 2
    EuglycemiaDiabetesPEuglycemiaDiabetesP
    N16223030
    Age, years53.79 (10.72)56.10 (9.86)0.49847.81 (11.65)55.14 (6.99)0.005
    BMI, kg/m225.41 (4.19)39.16 (9.33)<0.00135.01 (7.49)35.45 (6.64)0.811
    Glucose, mg/dL91.80 (5.25)161.05 (88.32)0.00592.37 (5.65)165.60 (71.64)<0.001
    LDL, mg/dL112.33 (37.88)108.18 (37.72)0.745108.77 (40.34)108.80 (43.21)0.998
    HDL, mg/dL55.40 (11.34)45.82 (11.13)0.01550.67 (11.46)44.70 (13.23)0.067
    Nonsmoking, n (%)12 (75.0)13 (65.0)0.77715 (57.7)24 (88.9)0.024
    AA race, n (%)6 (37.5)10 (45.5)0.87520 (66.7)19 (63.3)1.000
    Women, n (%)9 (56.2)14 (63.6)0.90120 (66.7)15 (50.0)0.295
    • Mean (SD) is shown for continuous variables and analyzed by one-way ANOVA, unless otherwise indicated. χ2 goodness-of-fit test was used to analyze differences for categorical variables. AA, African American.

  • Table 2

    Clinical characteristics of longitudinal cohort

    TimeNoDx→NoDxNoDx→DMPreDM→DMP
    N191920
    Age, yearsTime 142.50 (8.26)47.84 (8.58)47.69 (8.68)0.095
    Time 247.60 (8.75)52.76 (8.50)52.21 (8.84)0.141
    BMI, kg/m2Time 133.10 (5.60)35.40 (7.66)35.56 (9.11)0.540
    Time 233.92 (5.48)36.63 (9.41)35.44 (8.63)0.585
    Glucose, mg/dLTime 189.42 (4.14)93.26 (9.13)110.55 (6.06)<0.001
    Time 289.58 (6.13)125.53 (40.68)131.55 (45.81)0.001
    LDL, mg/dLTime 1132.63 (38.20)133.05 (31.06)118.45 (32.13)0.315
    Time 2123.53 (33.66)119.42 (37.89)119.15 (36.06)0.915
    HDL, mg/dLTime 150.95 (14.25)50.05 (11.97)42.55 (10.21)0.070
    Time 255.84 (11.55)53.47 (15.21)44.80 (11.01)0.022
    Nonsmoking, n (%)Time 15 (50.0)6 (33.3)10 (55.6)0.389
    Time 25 (35.7)8 (50.0)8 (44.4)0.783
    White race, n (%)7 (36.8)5 (26.3)8 (40.0)0.645
    Women, n (%)14 (73.7)12 (63.2)14 (70)0.776
    • Mean (SD) is shown for continuous variables and analyzed by one-way ANOVA, unless otherwise indicated. χ2 goodness-of-fit test was used to analyze differences for categorical variables. DM, diabetes; NoDx, euglycemia; PreDM, prediabetes.

PreviousNext
Back to top
Diabetes: 67 (11)

In this Issue

November 2018, 67(11)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Altered Extracellular Vesicle Concentration, Cargo, and Function in Diabetes
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Altered Extracellular Vesicle Concentration, Cargo, and Function in Diabetes
David W. Freeman, Nicole Noren Hooten, Erez Eitan, Jamal Green, Nicolle A. Mode, Monica Bodogai, Yongqing Zhang, Elin Lehrmann, Alan B. Zonderman, Arya Biragyn, Josephine Egan, Kevin G. Becker, Mark P. Mattson, Ngozi Ejiogu, Michele K. Evans
Diabetes Nov 2018, 67 (11) 2377-2388; DOI: 10.2337/db17-1308

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Altered Extracellular Vesicle Concentration, Cargo, and Function in Diabetes
David W. Freeman, Nicole Noren Hooten, Erez Eitan, Jamal Green, Nicolle A. Mode, Monica Bodogai, Yongqing Zhang, Elin Lehrmann, Alan B. Zonderman, Arya Biragyn, Josephine Egan, Kevin G. Becker, Mark P. Mattson, Ngozi Ejiogu, Michele K. Evans
Diabetes Nov 2018, 67 (11) 2377-2388; DOI: 10.2337/db17-1308
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Research Design and Methods
    • Results
    • Discussion
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • A High-Fat Diet Attenuates AMPK α1 in Adipocytes to Induce Exosome Shedding and Nonalcoholic Fatty Liver Development In Vivo
  • Multinucleated Giant Cells in Adipose Tissue Are Specialized in Adipocyte Degradation
  • CEPT1-Mediated Phospholipogenesis Regulates Endothelial Cell Function and Ischemia-Induced Angiogenesis Through PPARα
Show more Pathophysiology

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.